Cloudbreak Pharma Inc., a U.S.-based biopharmaceutical company, has entered into a strategic partnership with Japanese pharmaceutical firm Santen Pharmaceutical. The collaboration focuses on the development, manufacturing, and commercialization of Cloudbreak’s investigational drug, CBT-001, across Southeast Asia, including key markets such as Japan, Korea, Vietnam, Thailand, Malaysia, the Philippines, Singapore, and Indonesia. As per the terms of the agreement, Cloudbreak Pharma is set to receive an upfront payment and potential milestone payments totaling up to USD 91 million, in addition to a double-digit percentage of future net sales as royalties.
CBT-001 is an innovative emulsified nintedanib, a multi-kinase inhibitor that targets VEGF (vascular endothelial growth factor), PDGF (platelet-derived growth factor), and FGF (fibroblast growth factor) receptors. The drug is designed to inhibit angiogenesis and fibrosis, making it a potential treatment for pterygium. CBT-001 is currently undergoing a global, multi-center Phase III study in the U.S., China, Australia, New Zealand, and India, following the successful completion of a Phase II study in the U.S.
Pterygium, a non-malignant abnormal proliferation of fibrous vascular tissue on the ocular surface, originates from the conjunctiva and can extend to the corneal surface. Despite its prevalence, there are currently no approved drugs for the treatment of pterygium on the market. The standard of care typically involves the use of artificial tears and short-term topical eye steroids, which have not been specifically clinically approved for this condition.- Flcube.com
